Søgning på udtrykket 'omicron' giver 43 resultater
Dokumenter [3] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]
Dokumenter [3]
Ændringer siden sidste udgave: 1. Simplificering af risikogrupper. 2. Skærpelse af kriterier for opstart af behandling hos indlagte patienter, f.eks. blodgas analyse før remdesivir. 3. Information om høj pris på paxlovid og højere NNT for beskyttelse mod alvorligt forløb siden primærpublikation.
Denne vejledning er tiltænkt diagnostik og behandling af COVID-19. Denne retningslinje vil løbende blive opdateret, som ny evidens kommer frem. Der er ikke foretaget en gradering af evidensniveau. Ændringer i denne udgave: Remdesivir står ikke længere som relativt kontraindiceret ved påvirket nyrefunktion.
Denne vejledning er tiltænkt diagnostik og behandling af COVID-19. Denne retningslinje vil løbende blive opdateret, som ny evidens kommer frem. Der er ikke foretaget en gradering af evidensniveau. Ændringer i denne udgave: 1. Et af Paxlovid kriterierne ændret (fra ”Betydelige symptomer på COVID-19” til ”Mild eller moderat COVID-19”). 2. Døde links til infektionshygiejniske retningslinjer er fjernet, og nyt er indsat. 3. Tekst om afisolation.
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
Nature
18.04.2024
Infection
13.04.2024
. Abstract. . Purpose. To evaluate clinical outcomes associated with sotrovimab use during Omicron BA.2 and BA.5 predominance. . . . Methods. Electronic databases were searched for observational studies published in peer-reviewed journals, preprint articles and conference abstracts from January 1, 2022 to February 27, 2023. . . …
International Journal of Infectious Diseases
12.04.2024
Although the overall mortality during SARS-CoV-2 Omicron variants of concern (VoC) wave might be lower than that seen with other previous VoCs immunocompromised individuals remain at increased the risk of hospitalization and prolonged duration of the infection compared to the general population [1]. Moreover, persons with immunosuppression may experience reduced vaccine immune response with an impaired seroconversion and effectiveness [2]. To address the need to protect these individuals from breakthrough i…
Infection
11.04.2024
. Abstract. . Purpose. To evaluate clinical outcomes associated with sotrovimab use during Omicron BA.2 and BA.5 predominance. . . . Methods. Electronic databases were searched for observational studies published in peer-reviewed journals, preprint articles and conference abstracts from January 1, 2022 to February 27, 2023. . . …
Infection
10.04.2024
Infection
8.04.2024
The Lancet Microbe
4.04.2024
We propose that prolonged detection of WI-CL-001 in wastewater indicates persistent shedding of SARS-CoV-2 from a single human initially infected by an ancestral B.1.234 virus. The accumulation of convergent omicron-like mutations in WI-CL-001’s ancestral B.1.234 genome probably reflects persistent infection and extensive within-host evolution. People who shed cryptic lineages could be an important source of highly divergent viruses that sporadically emerge and spread.
BMC Infectious Diseases
30.03.2024
. Abstract. . Background. The prevalence and distinction between first Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and reinfection with the Omicron variant among healthcare workers (HCWs) remain unclear. . . . Methods. A cross-sectional study was conducted at a hospital in Southern China. The study included 262 HCW…
BMC Infectious Diseases
28.03.2024
. Abstract. . Background. The prevalence and distinction between first Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and reinfection with the Omicron variant among healthcare workers (HCWs) remain unclear. . . . Methods. A cross-sectional study was conducted at a hospital in Southern China. The study included 262 HCW…
Journal of Medical Virology
23.03.2024
Journal of Medical Virology, Volume 96, Issue 3, March 2024.
Journal of Medical Virology
22.03.2024
Journal of Medical Virology, Volume 96, Issue 3, March 2024.
Journal of Medical Virology
20.03.2024
Journal of Medical Virology, Volume 96, Issue 3, March 2024.
Lancet Infectious Diseases
20.03.2024
mRNA-1273.214 was immunogenic against BA.1 and D614G in children aged 6 months to 5 years, with a comparable safety profile to mRNA-1273, when given as a two-dose primary series or a booster dose. These results are aligned with the US Centers for Disease Control and Prevention recommendations for the use of variant-containing vaccines for continued protection against the emerging variants of SARS-CoV-2.
Journal of the American Medical Association
19.03.2024
Experts detected a strain of SARS-CoV-2 with more than 30 changes in its spike protein compared with Omicron subvariant XBB.1.5, the US Centers for Disease Control and Prevention (CDC) announced. The newer Omicron subvariant, known as BA.2.87.1, has infected at least 9 people in South Africa since September 2023. No cases have been reported in the US or outside South Africa, the CDC noted in its update.
Journal of Medical Virology
19.03.2024
Journal of Medical Virology, Volume 96, Issue 3, March 2024.
PLoS One Infectious Diseases
19.03.2024
by Hsiao-Hui Tsou, Fang-Jing Lee, Shiow-Ing Wu, Byron Fan, Hsiao-Yu Wu, Yu-Hsuan Lin, Ya-Ting Hsu, Chieh Cheng, Yu-Chieh Cheng, Wei-Ming Jiang, Hung-Yi Chiou, Wei J. Chen, Chao A. Hsiung, Pau-Chung Chen, Huey-Kang Sytwu . Background Taiwan was a coronavirus disease 2019 (COVID-19) outlier, with an extraordinarily long transmission-free record: 253 days without locally transmitted infections while the rest of the world battled wave after wave of infection. The appearance of the alpha variant in May 2021, cl…
PLoS One Infectious Diseases
15.03.2024
…Background This study evaluated the clinical characteristics of patients with COVID-19 in Korea, and examined the relationship between severe COVID-19 cases and underlying health conditions during the Delta (September 20, 2021 to December 4, 2021) and the Omicron (February 20, 2022 to March 31, 2022) predominant period. Methods This study assessed the association between critical COVID-19 illness and various risk factors, including a variety of underlying health conditions, using multiple logistic regressi…
Lancet Infectious Diseases
7.03.2024
All three coprimary endpoints were met in part 2 of the ongoing 2019nCoV-311 study. These data support the development of monovalent and/or bivalent vaccines for the most currently circulating variants, to optimise protection. With no new safety findings, further investigation of omicron-based subvariant vaccines is supported by the evidence.
The Lancet Microbe
6.03.2024
In this cohort, prolonged replication-competent omicron SARS-CoV-2 infections were uncommon. Within-host evolutionary rates were similar across patients, but individuals with infections lasting longer than 56 days accumulated spike mutations, which were distinct from those seen globally. Populations at high risk should be targeted for repeated testing and treatment and monitored for the emergence of antiviral resistance.
Journal of Medical Virology
5.03.2024
Journal of Medical Virology, Volume 96, Issue 3, March 2024.
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?Morbidity and Mortality Weekly Report (MMWR)
19.04.2024
This report describes the duration of protection provided by the original monovalent COVID-19 vaccines.
Eurosurveillance latest updates
8.03.2024
We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23–55) in 18–59-year-olds and 50% (95% CI: 44–56) in 60–85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2–6.5) and, not stat…
Eurosurveillance latest updates
16.02.2024
… Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (67%; 95% CI: 48–80), and lowest against influenza A(H3N2) (40%; 95% CI: 5–61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21–65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28–85). .
Morbidity and Mortality Weekly Report (MMWR)
2.02.2024
This report describes vaccine effectiveness for the updated COVID-19 vaccine in preventing symptomatic SARS-CoV-2 infection.
Eurosurveillance latest updates
19.01.2024
We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14…
Eurosurveillance latest updates
24.11.2023
…sure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). . . Methods. In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received
Eurosurveillance latest updates
10.11.2023
. Background. The earliest recognised infections by the SARS-CoV-2 Omicron variant (Pango lineage B.1.1.529) in Belgium and Switzerland suggested a connection to an international water polo tournament, held 12–14 November 2021 in Brno, Czechia. . . Aim. To study the arrival and subsequent spread of the Omicron variant in Belgium and Switzerland, and understand the overall importance of this international sporting event on the number of infections in the two countries. . . Methods. We performed intensi…
Morbidity and Mortality Weekly Report (MMWR)
26.10.2023
CDC detected BA.2.86 variant in a traveler within days of being reported. Timely detection provides early warning of new COVID-19 variants entering the U.S.
Morbidity and Mortality Weekly Report (MMWR)
29.09.2023
This report describes how young infants of people who received a COVID-19 vaccine while pregnant were less likely to be hospitalized or experience serious complications from COVID-19.
Eurosurveillance latest updates
22.09.2023
…sitivity and specificity of selected antigen detection rapid diagnostic tests (AG-RDTs) for SARS-CoV-2 were determined in the unvaccinated population when the Delta variant was circulating. Viral loads, dynamics, symptoms and tissue tropism differ between Omicron and Delta. . . Aim. We aimed to compare AG-RDT sensitivity and specificity in selected subgroups during Omicron vs Delta circulation. . . Methods. We retrospectively paired AG-RDT results with PCRs registered in Czechia’s Information System f…
Medscape Infectious Diseases
20.09.2023
The American College of Physicians has issued an updated version of its living, rapid practice point guideline on the best treatment options for outpatients with confirmed COVID-19. . MDedge News
Eurosurveillance latest updates
8.09.2023
…ants during periods when two variants were co-circulating. The study protocol and its associated statistical analysis code was applied by investigators in Denmark, England, Luxembourg, Norway, Portugal and Scotland to assess the severity of cases with the Omicron BA.1 virus variant relative to Delta. After pooling estimates using meta-analysis methods (random effects estimates), the risk of hospital admission (adjusted hazard ratio (aHR) = 0.41; 95% confidence interval (CI): 0.31−0.54), admission to i…
Medscape Infectious Diseases
14.08.2023
Most Canadians now have hybrid immunity against SARS-CoV-2 through a combination of infection and vaccination, but certain groups remain vulnerable. . Medscape Medical News
Eurosurveillance latest updates
11.08.2023
During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April–June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warranted …
Morbidity and Mortality Weekly Report (MMWR)
11.08.2023
This report describes rates of SARS-CoV-2 infection and COVID-19 related deaths were higher among maintenance dialysis patients compared to rates in the U.S. population.
Morbidity and Mortality Weekly Report (MMWR)
16.06.2023
This report describes how multiple omicron lineages were identified using genomic surveillance.
Medscape Infectious Diseases
31.05.2023
The research team evaluated data from 8646 adults who had COVID-19 at different times during the pandemic and from 1118 persons who had not had COVID. . WebMD Health News
Eurosurveillance latest updates
5.05.2023
. Background. Following the SARS-CoV-2 Omicron variant spread, the use of unsupervised antigenic rapid diagnostic tests (self-tests) increased. . . Aim. This study aimed to measure self-test uptake and factors associated with self-testing. . . Methods. In this cross-sectional study from 20 January to 2 May 2022, the case series from a case–control study on factors associated with SARS-CoV-2 infection were used to analyse self-testing habits in France. A multivariable quasi-Poisson regression was used…
Morbidity and Mortality Weekly Report (MMWR)
27.04.2023
This report describes effectiveness of monovalent mRNA vaccination in preventing COVID-19-associated invasive mechanical ventilation and death.
Eurosurveillance latest updates
22.04.2023
. Background. There are conflicting reports on the performance of rapid antigen detection tests (RDT) in the detection of the SARS-CoV-2 Omicron (B.1.1.529) variant; however, these tests continue to be used frequently to detect potentially contagious individuals with high viral loads. . . Aim. The aim of this study was to investigate comparative detection of the Delta (B.1.617.2) and Omicron variants by using a selection of 20 RDT and a limited panel of pooled combined oro- and nasopharyngeal clinical Del…